Organization | Friedrich Schiller University

Friedrich Schiller University Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Jena Germany (1558)

Organization Overview

First Clinical Trial

2000

NCT00940576

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Center for Clinical Studies, University Hospital Jena, Germany | Center for Sepsis Control and Care, Germany | Center of neuroendocrine tumors, Zentralklinik Bad Berka | Department of general-, visceral- and vascular surgery, University of Jena | Department of Nutrition, University Jena | Department of Obstetrics, Jena University Hospital | Department of Urology, University Hospital Jena | Friedrich Schiller University Jena | Friedrich-Schiller-University Jena | Friedrich Schiller University Jena, Department of Nutritional Physiology | Friedrich Schiller University Jena, Institute of Nutrition | Friedrich Schiller University Jena, Institute of Nutrition, Department of Nutrional Physiology | Friedrich Schiller University Jena, Institute of Nutrition, Department of Nutritional Physiology | Friedrich-Schiller-University Jena, Institute of Nutrition, Department of Nutritional Physiology | Friedrich-Schiller-University Jena, Institute of Nutrition, Department of Nutritional Toxicology | Friedrich Schiller University Jena, Institute of Nutrition, RG Bioactice Plant Products | F.-Schiller-University Jena, Germany | FSU Jena | Institute of Medical Statistics, Computer Sciences and Documentation, University Hospital Jena, Germany | Jena University Hospital | Klinik Innere Medizin III, Medical School, Friedrich Schiller University | Sebastian Scholl, PD Dr. med. | Thomas Ernst, PD Dr. med. | UNIVERSITAETSKLINIKUM JENA, Jena, Germany | Universital Hospital Jena | University Hopitel Jena, Institute for Medical Chemistry | University Hospital Jena | University Hospital, Jena | University Hospital Jena; Dep. of Anesthesiology and Intensive Care Medicine | University Hospital Jena, Dept. of Anesthesiology and Intensive Care Medicine | University Hospital Jena; Dept. of Anesthesiology an Intensive Care Medicine | University Hospital Jena, Radiology Department, Germany | University Hospital of Jena, Center of Infectious Diseases and Infection Control | University of Jena | University of Jena, Children`s hospital | University of Jena, Dept. of Nutritional Physiology | University of Jena, Hospital for gynaecology and obstetrics | University of Jena, Insitute of Nutrition | University oj Jena, Department of Nutritional Biochemistry and Physiology; Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD), Halle-Jena-Leipzig, Germany

Active Ingredients

Drugs in Phase 4 Trials (7)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (1 trial)

amisulpride (BARHEMSYS) (1 trial)

haloperidol (haldol) (3 trials)

lorazepam (ativan) (1 trial)

olanzapine (zyprexa) (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (1 trial)

risperidone (risperdal) (1 trial)

Drugs in Phase 3 Trials (23)

aciclovir (zovirax) (1 trial)

albumin (Human) (Plasbumin) (1 trial)

dalteparin (fragmin) (1 trial)

darolutamide (Nubeqa) (1 trial)

dasatinib (sprycel) (2 trials)

docetaxel (taxotere) (2 trials)

dornase alfa (pulmozyme) (2 trials)

gemcitabine (gemzar) (1 trial)

human fecal microbiota (Reybota) (1 trial)

hydroxyethyl starch (voluven) (1 trial)

insulin human (humulin) (2 trials)

interferon alpha-2b (Intron-A) (1 trial)

lenalidomide (revlimid) (1 trial)

meropenem (merrem) (1 trial)

moxifloxacin (avelox) (1 trial)

multivitamins (1 trial)

nilotinib (tasigna) (2 trials)

pentaerythrityl tetranitrate (Pentalong) (1 trial)

potassium citrate (urocit-k) (1 trial)

procalcitonin (1 trial)

selenium (2 trials)

sodium chloride (2 trials)

Drugs in Phase 2 Trials (23)

asciminib (Scemblix) (1 trial)

bortezomib (velcade) (1 trial)

bosutinib (bosulif) (1 trial)

cetuximab (erbitux) (1 trial)

cisplatin (platinol) (1 trial)

colistin (1 trial)

dihomo-gamma-linolenic acid (1 trial)

empagliflozin (jardiance) (1 trial)

epirubicin (ellence) (1 trial)

fish oil (Omegavan) (2 trials)

fluorouracil (efudex) (2 trials)

ifx-1 (2 trials)

imatinib (gleevec) (1 trial)

infliximab (remicade) (1 trial)

lactobacillus casei (1 trial)

leucovorin (1 trial)

midostaurin (rydapt) (1 trial)

pembrolizumab (keytruda) (1 trial)

rituximab (rituxan) (1 trial)

ruxolitinib (jakafi) (1 trial)

tetranitropentaerythritol (1 trial)

tobramycin (nebcin) (1 trial)

venetoclax (venclexta) (1 trial)

Drugs in Phase 1 Trials (5)

echium oil (1 trial)

icosapent ethyl (vascepa) (8 trials)

linseed oil (3 trials)

vitamin c (1 trial)

vitamin e (1 trial)

Drugs in Other Trials (25)

arginine (1 trial)

autologous microbiome (2 trials)

beta-glucans (1 trial)

betahistine mesilate (1 trial)

black currant (1 trial)

brazil nut (1 trial)

calcium (3 trials)

calcium carbonate (1 trial)

calcium phosphate (2 trials)

chlorella (1 trial)

cocoa powder (1 trial)

conjugated linoleic acid (1 trial)

fatty acid (1 trial)

kale extract (2 trials)

legume kernel fiber (1 trial)

mannitol (Osmitrol) (1 trial)

mare milk (2 trials)

nannochloropsis (1 trial)

phosphate (1 trial)

sirolimus (rapamune) (1 trial)

vitamin d3 (1 trial)

wheat (1 trial)

xanthophyll (3 trials)

zeaxanthin (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Abortion, Habitual (Phase 3)

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Colorectal Neoplasms (Phase 2)

Cystic Fibrosis (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Encephalitis (Phase 2)

Fatty Liver (Phase 2)

Fetal Growth Retardation (Phase 3)

Fibrosis (Phase 3)

Hashimoto Disease (Phase 2)

Heart Failure (Phase 2)

Hypercholesterolemia (Phase 1)

Inflammatory Bowel Diseases (Phase 3)

Kidney Diseases (Phase 2)

Leukemia (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myeloid, Chronic-Phase (Phase 2)

Liver Diseases (Phase 2)

Mouth Neoplasms (Phase 2)

Multiple Myeloma (Phase 3)

Neoplasm, Residual (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Non-alcoholic Fatty Liver Disease (Phase 2)

Oropharyngeal Neoplasms (Phase 2)

Overweight (Phase 1)

Pancreatic Neoplasms (Phase 3)

Pneumococcal Infections (Phase 4)

Pseudomonas Infections (Phase 2)

Schizophrenia (Phase 4)

Sepsis (Phase 3)

Shock (Phase 3)

Shock, Septic (Phase 3)

Sinusitis (Phase 3)

Systemic Inflammatory Response Syndrome (Phase 2)

Toxemia (Phase 3)

Ulcer (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 77
# of Trial APIs: 83